Simplex Trading’s Kymera Therapeutics KYMR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$91.7K Buy
800
+600
+300% +$51.6K ﹤0.01% 5662
2026
Q1
$16.7K Hold
200
﹤0.01% 6913
2025
Q4
$15.6K Buy
+200
New +$13.5K ﹤0.01% 6689
2025
Q3
Sell
-5,600
Closed -$244K 9569
2025
Q2
$244K Buy
+5,600
New +$193K ﹤0.01% 4291
2024
Q4
Sell
-300
Closed -$14K 9113
2024
Q3
$14K Hold
300
﹤0.01% 6949
2024
Q2
$8K Buy
+300
New +$10.4K ﹤0.01% 7587
2024
Q1
Sell
-200
Closed -$5K 9371
2023
Q4
$5K Sell
200
-200
-50% -$3.58K ﹤0.01% 7866
2023
Q3
$5K Sell
400
-200
-33% -$4.02K ﹤0.01% 7663
2023
Q2
$13K Hold
600
﹤0.01% 7170
2023
Q1
$17K Sell
600
-1,700
-74% -$54.8K ﹤0.01% 7069
2022
Q4
$57K Sell
2,300
-2,800
-55% -$74.7K ﹤0.01% 5703
2022
Q3
$111K Buy
+5,100
New +$134K ﹤0.01% 5373
2022
Q2
Sell
-33,800
Closed -$1.43M 10552
2022
Q1
$1.43M Buy
33,800
+33,500
+11,167% +$1.41M ﹤0.01% 2466
2021
Q4
$19K Sell
300
-700
-70% -$40.8K ﹤0.01% 8412
2021
Q3
$56K Hold
1,000
﹤0.01% 7381
2021
Q2
$48K Buy
+1,000
New +$43.4K ﹤0.01% 7682

Other funds holding KYMR

Simplex Trading's KYMR Position: Q2 2026 in Review

Simplex Trading opened a new position in Kymera Therapeutics (KYMR) in Q2 2026: 5,867 shares worth $673K. The stake represents ﹤0.01% of the portfolio and ranks #3253 among its holdings. This is a return to the name: Simplex Trading previously reported a position in KYMR as recently as Q4 2024.

Simplex Trading first reported a position in KYMR in Q2 2021 and has held it in 8 quarters since. 277 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Simplex Trading held 5,867 shares of Kymera Therapeutics worth $673K as of Q2 2026.
  • Kymera Therapeutics was a new Simplex Trading position in Q2 2026.
  • Kymera Therapeutics made up ﹤0.01% of Simplex Trading's portfolio in Q2 2026, its #3253 holding.
  • Simplex Trading first reported a position in Kymera Therapeutics in Q2 2021 and has held it in 8 quarters since.
  • 277 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Simplex Trading's 13F filing for Q2 2026, filed 12 Aug 2026.